The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Abstract
Two thousand three hundred and thirty two nonselected brains from 1- to 100-year-old individuals were examined using immunocytochemistry (AT8) and Gallyas silver staining for abnormal tau; immunocytochemistry (4G8) and Campbell-Switzer staining were used for the detection ofβ-amyloid. A total of 342 cases was negative in the Gallyas stain but when restaged for AT8 only 10 were immunonegative. Fifty-eight cases had subcortical tau predominantly in the locus coeruleus, but there was no abnormal cortical tau (subcortical Stages a-c). Cortical involvement (abnormal tau in neurites) was identified first in the transentorhinal region (Stage 1a, 38 cases). Transentorhinal pyramidal cells displayed pretangle material (Stage 1b, 236 cases). Pretangles gradually became argyrophilic neurofibrillary tangles (NFTs) that progressed in parallel with NFT Stages I to VI. Pretangles restricted to subcortical sites were seen chiefly at younger ages. Of the total cases, 1,031 (44.2%) had β-amyloid plaques. The first plaques occurred in the neocortex after the onset of tauopathy in the brainstem. Plaques generally developed in the 40s in 4% of all cases, culminating in their tenth decade (75%). β-amyloid plaques and NFTs were significantly correlated (p < 0.0001). These data suggest that tauopathy associated with sporadic Alzheimer disease may begin earlier than previously thought and possibly in the lower brainstem rather than in the transentorhinal region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Up to 60% of CU individuals over age 80 years have AD neuropathologic changes at autopsy or by biomarkers [60,152,212–214].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [213]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“screening revealed low rates of Braak 1–2 NFT stages in all three groups (Table 2), consistent with literature-based norms [3].”
From Tuberous sclerosis complex is associated with a novel human tauopathy (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It should be noted that tau aggregation in the brain is associated with older age and is generally uncommon in healthy young adults (Braak et al., 2011; Crary et al., 2014).”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Braak et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Medial temporal and brainstem neurofibrillary changes were observed in our older TSC subjects, as expected, but at a rate comparable to that observed in the epilepsy and non-neurological control groups and age-based norms [3].”
From Tuberous sclerosis complex is associated with a novel human tauopathy (2023) · cites this paper as [3]
In the citing paper
“In individuals with autosomal dominant mutations in genes coding for amyloid precursor protein (APP) or Presenilin 119 , alterations in Aβ generation that result in early deposition of plaque initiate the disease and patients invariably develop the full spectrum of tau pathology 120,121 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [121]
In the citing paper
“NFTs first appear in layer II of the entorhinal cortex (EC) during AD onset.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [231]
In the citing paper
“NFTs subsequently appear in interconnected anatomical regions within the brain, including the hippocampus and neocortex during neurodegenerative progression [229–231].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [231]
In the citing paper
“Furthermore, it impairs adult hippocampal neurogenesis in mice and affects cortical thickness, brain activity, and mitochondrial function well before significant Aβ accumulation in the human brains [74–76].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [76]
In the citing paper
“Most of all, this binary threshold does not reflect the reality of amyloid β and tau pathology, which is continuous and present at a minimal extent in almost all people older than 70 years,17 with important discrepancies between pathology burden and clinical symptoms at intermediate extents (panel 2).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [17]
In the citing paper
“For tau biomarkers, there is also a strong discrepancy between neuropathological identification (in post-mortem studies, the presence of tau Braak stages I–II is almost universal after age 70 years)17,19 and in-vivo measures of tau aggregates on PET (36% of individuals are tau positive after the age of 70 years23).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [17]
In the citing paper
“The concordance of genetics and Aβ deposition is aligned with CPC studies that indicate that AβPs may be a temporally “upstream” feature of the neocortical disease, with the caveats that brainstem and medial temporal lobe pretangles and NFTs are seen in subjects without Aβ deposition in all age categories (33, 39, 44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“In contrast to NFTs, AβPs are extracellular (45, 46) and are found in a high proportion of all elderly persons but are not universal (44, 47, 48).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Recently, it has been reported that NFTs are also very common in certain brainstem nuclei in subjects without dementia (39-44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Neurofibrillary pathology is observed in the human brain long before Aβ plaques develop (39, 44, 300).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“Neuritic plaques seem to develop after diffuse AβPs and NFTs (44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
In the citing paper
“At 40 years, all individuals studied by Braak and Del Tredici (39) and Braak et al (44) exhibited at least initial neurofibrillary pathology in the brainstem (Fig. 5).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“The first lesions were usually seen in the transentorhinal region (2).”
BackgroundSelf-citationThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Self-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationA Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,153
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,010
Hickman, R. A., Flowers, X. E., & Wısnıewskı, T. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01063-1 · Cited by 48
Kelly, L., Seifi, M., Ma, R., Mitchell, S. J., Rudolph, U., Viola, K. L., Klein, W. L., Lambert, J. J., & Swinny, J. D. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12674 · Cited by 48
Bengoa‐Vergniory, N., Velentza‐Almpani, E., Silva, A. M., Scott, C., Vargas‐Caballero, M., Sastre, M., Wade‐Martins, R., & Alegre‐Abarrategui, J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01117-y · Cited by 48
Davis, G. A., Castellani, R. J., & McCrory, P. (2015) · Neurosurgery · doi:10.1227/neu.0000000000000722 · Cited by 47
Hussain, R., Khan, S., Ullah, H., Ali, F., Khan, Y., Sardar, A., Iqbal, R., Ataya, F. S., El-Sabbagh, N. M., & Batiha, G. E. (2023) · Pharmaceuticals · doi:10.3390/ph16091278 · Cited by 47
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
Kron, J. O.-Z. J., Keenan, R. J., Hoyer, D., & Jacobson, L. H. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-040323-031929 · Cited by 47
Ravikumar, S., Denning, A. E., Lim, S., Chung, E. P., Sadeghpour, N., Ittyerah, R., Wisse, L. E. M., Das, S. R., Xie, L., Robinson, J. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49205-0 · Cited by 47
Polydoro, M., de Calignon, A., Suárez‐Calvet, M., Sanchez, L., Kay, K. R., Nicholls, S. B., Roe, A. D., Pitstick, R., Carlson, G. A., Gómez‐Isla, T., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0881-13.2013 · Cited by 47
Age effects on the P300 potential and the corresponding fMRI BOLD-signal
Juckel, G., Karch, S., Kawohl, W., Kirsch, V., Jäger, L., Leicht, G., Lutz, J., Stammel, A., Pogarell, O. M., Ertl, M., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.019 · Cited by 47
Energy and the Alzheimer brain
Mamelak, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.001 · Cited by 47
Of Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia
Boccardi, V., Comanducci, C., Baroni, M., & Mecocci, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122672 · Cited by 47
Talboom, J. S., Haberg, A. K., Both, M. D. D., Naymik, M., Schrauwen, I., Lewis, C. R., Bertinelli, S. F., Hammersland, C., Fritz, M. A., Myers, A., et al. (2019) · eLife · doi:10.7554/elife.46179 · Cited by 47
Brain pyrimidine nucleotide synthesis and Alzheimer disease
Pesini, A., Iglesias, E., Bayona‐Bafaluy, M. P., Garrido-Pérez, N., Meade, P., Gaudó, P., Jiménez-Salvador, I., Andrés‐Benito, P., Montoya, J., Ferrer, I., et al. (2019) · Aging · doi:10.18632/aging.102328 · Cited by 47
Díaz-Román, M., Pulopulos, M. M., Baquero, M., Salvador, A., Cuevas, A., Ferrer, I., Ciopat, O., & Gómez, E. (2020) · SLEEP · doi:10.1093/sleep/zsaa133 · Cited by 47
Locus Coeruleus Magnetic Resonance Imaging in Neurological Diseases
Galgani, A., Lombardo, F. P., Latta, D. D., Martini, N., Bonuccelli, U., Fornai, F., & Giorgi, F. S. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01087-7 · Cited by 47
Slater, C. L., & Wang, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.397 · Cited by 47
Erdoğan, M., Köse, L. P., Eşsiz, S., & Gülçın, İ. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100113 · Cited by 47
Egroo, M. V., Riphagen, J. M., Ashton, N. J., Janelidze, S., Sperling, R. A., Johnson, K. A., Yang, H., Bennett, D. A., Blennow, K., Hansson, O., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02041-y · Cited by 46
Eltom, K., Mothes, T., Libard, S., Ingelsson, M., & Erlandsson, A. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01745-8 · Cited by 46
Arendt, T., Stieler, J., & Holzer, M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1342-8 · Cited by 46
An effective treatment for Alzheimer's disease must consider both amyloid and tau
Lansdall, C. J. (2014) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzu002 · Cited by 46
Tasaki, M., Ueda, M., Hoshii, Y., Mizukami, M., Matsumoto, S., Nakamura, M., Yamashita, T., Ueda, A., Misumi, Y., Masuda, T., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5203 · Cited by 46
Klein, C., Roussel, G., Brun, S., Rusu, C., Patte‐Mensah, C., Maître, M., & Mensah‐Nyagan, A. G. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0640-z · Cited by 46
Circulating antioxidants and Alzheimer disease prevention: a Mendelian randomization study
Williams, D. M., Hägg, S., & Pedersen, N. L. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy225 · Cited by 46
Spiers, J. G., Chen, H. C., Bourgognon, J.-M., & Steinert, J. R. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.01.025 · Cited by 46
Calderón‐Garcidueñas, L., González-Maciel, A., Kulesza, R. J., González‐González, L. O., Reynoso-Robles, R., Mukherjee, P. S., & Torres‐Jardón, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190331 · Cited by 46
Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer’s disease
Kang, S. S., Ahn, E. H., & Ye, K. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00494-7 · Cited by 46
Banning, L. C. P., Ramakers, I. H. G. B., Rosenberg, P. B., Lyketsos, C. G., Leoutsakos, J., & Initiative, A. D. N. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5418 · Cited by 46
Brainstem Volumetric Integrity in Preclinical and Prodromal Alzheimer’s Disease
Dutt, S., Initiative, A. D. N., Li, Y., Mather, M., & Nation, D. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200187 · Cited by 46
Kelberman, M. A., Keilholz, S. D., & Weinshenker, D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.583421 · Cited by 46
Tosun, D., Demir, Z., Veitch, D. P., Weintraub, D. A., Aisen, P. S. S., Jack, C. R., Jagust, W., Petersen, R. C., Saykin, A. J., Shaw, L. M. J., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12480 · Cited by 46
The subcortical default mode network and Alzheimer’s disease: a systematic review and meta-analysis
Seoane, S., van den Heuvel, M. P., Acebes, Á., & Janssen, N. (2024) · Brain Communications · doi:10.1093/braincomms/fcae128 · Cited by 45
Prion Disease Induces Alzheimer Disease—Like Neuropathologic Changes
Tousseyn, T., Bajsarowicz, K., Sanchez, H. C., Gheyara, A. L., Oehler, A., Geschwind, M., DeArmond, B., & DeArmond, S. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000228 · Cited by 45
Modelling human pathology of traumatic brain injury in animal models
Risling, M., Smith, D. H., Stein, T. D., Thelin, E. P., Zanier, E. R., Ankarcrona, M., & Nilsson, P. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12909 · Cited by 45
Hemaida, A. Y., Hassan, G. S., Maarouf, A. R., Joubert, J., & El-Emam, A. A.-R. (2021) · ACS Omega · doi:10.1021/acsomega.1c02549 · Cited by 45
Plini, E. R. G., O’Hanlon, E., Boyle, R. T., Sibilia, F., Rikhye, G., Kenney, J. P. M., Whelan, R., Melnychuk, M. C., Robertson, I. H., & Dockree, P. M. (2021) · Cells · doi:10.3390/cells10071829 · Cited by 45
Association between Sleep, Alzheimer’s, and Parkinson’s Disease
Matsumoto, S., & Tsunematsu, T. (2021) · Biology · doi:10.3390/biology10111127 · Cited by 45
Selective brain regional changes in lipid profile with human aging
Mota‐Martorell, N., Andrés‐Benito, P., Martin‐Garí, M., Galo‐Licona, J. D., Sol, J., Fernàndez‐Bernal, A., Portero‐Otín, M., Ferrer, I., Jové, M., & Pamplona, R. (2022) · GeroScience · doi:10.1007/s11357-022-00527-1 · Cited by 45
Jacobs, H. I. L., Becker, J. A., Kwong, K. K., Munera, D., Ramirez-Gomez, L. A., Engels, N., Sanchez, J. S., Vila‐Castelar, C., Baena, A. Y., Sperling, R. A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12656 · Cited by 45
The Impact of Intermittent Hypoxia on Metabolism and Cognition
Shobatake, R., Ota, H., Takahashi, N., Ueno, S., Sugie, K., & Takasawa, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112957 · Cited by 45
Engels, N., Koops, E. A., Prokopiou, P. C., Egroo, M. V., Schneider, C., Riphagen, J. M., Singhal, T., & Jacobs, H. I. L. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104998 · Cited by 45
Crosstalk between Oxidative Stress and Aging in Neurodegeneration Disorders
Abdelhamid, R. F., & Nagano, S. (2023) · Cells · doi:10.3390/cells12050753 · Cited by 44
Current concepts and molecular pathology of neurodegenerative diseases
Forrest, S. L., & Kovács, G. G. (2024) · Pathology · doi:10.1016/j.pathol.2024.10.006 · Cited by 44
Braak, H., & Tredici, K. D. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1153-2 · Cited by 44
Self-citationKinase–Kinase Interaction and Modulation of Tau Phosphorylation
Hashiguchi, M., & Hashiguchi, T. (2012) · International review of cytology · doi:10.1016/b978-0-12-405210-9.00004-7 · Cited by 44
CSF biomarkers in neurodegenerative and vascular dementias
Llorens, F., Schmitz, M., Ferrer, I., & Zerr, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.003 · Cited by 44
Deep Brain Stimulation for Alzheimer’s Disease: Tackling Circuit Dysfunction
Lam, J., Lee, J., Liu, C. Y., Lozano, A. M., & Lee, D. J. (2020) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13305 · Cited by 44
Rodríguez, J. L., Oltmer, J., Greve, D. N., Williams, E. M., Slepneva, N., Wang, R., Champion, S., Lang-Orsini, M., Fischl, B. R., Frosch, M. P., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215567 · Cited by 44
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 44
Self-citationOshima, E., Ishihara, T., Yokota, O., Nakashima‐Yasuda, H., Nagao, S., Ikeda, C., Naohara, J., Terada, S., & Uchitomi, Y. (2013) · Brain Pathology · doi:10.1111/bpa.12059 · Cited by 44
Zhang, M., Ganz, A. B., Rohde, S., Rozemuller, A. J. M., Bank, N. B., Reinders, M. J. T., Scheltens, P., Hulsman, M., Hoozemans, J. J. M., & Holstege, H. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12899 · Cited by 43
Stern, A. L., & Naidoo, N. N. (2015) · SpringerPlus · doi:10.1186/s40064-014-0777-6 · Cited by 44
Experimental Evidence of the Benefits of Acupuncture for Alzheimer's Disease: An Updated Review
Yu, C.-C., Du, Y., Wang, S., Liu, L.-B., Shen, F., Wang, L., Lin, Y.-F., & Kong, L.-H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.549772 · Cited by 43
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Tau deposition in young adults with drug-resistant focal epilepsy.
Smith, K. M., Blessing, M. M., Parisi, J. E., Britton, J. W., Mandrekar, J., & Cascino, G. D. (2019) · Epilepsia · doi:10.1111/epi.16375 · Cited by 42
LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease
Koper, M. J., Tomé, S. O., Gawor, K., Belet, A., Schoor, E. V., Schaeverbeke, J. M., Vandenberghe, R. R., Vandenbulcke, M., Ghebremedhin, E., Otto, M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01432-6 · Cited by 42
Self-citationPezzoli, S., Giorgio, J., Martersteck, A., Dobyns, L., Harrison, T. M., & Jagust, W. J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13438 · Cited by 42
Prà, I. D., Chiarini, A., Pacchiana, R., Gardenal, E., Chakravarthy, B., Whitfield, J., & Armato, U. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140828214701 · Cited by 42
Abner, E. L., Neltner, J. H., Jicha, G. A., Patel, E., Anderson, S., Wilcock, D. M., Eldik, L. J. V., & Nelson, P. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180514 · Cited by 42
Intake of Meat, Fish, Fruits, and Vegetables and Long-Term Risk of Dementia and Alzheimer’s Disease
Ngabirano, L., Samieri, C., Féart, C., Gabelle, A., Artéro, S., Duflos, C., Berr, C., & Mura, T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180919 · Cited by 42
Microglia and Other Myeloid Cells in Central Nervous System Health and Disease
Gopinath, A., Collins, A., Khoshbouei, H., & Streit, W. J. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265058 · Cited by 42
Gray matter atrophy patterns within the cerebellum-neostriatum-cortical network in SCA3
Guo, J., Chen, H., Biswal, B. B., Guo, X., Zhang, H., Dai, L., Zhang, Y., Li, L., Fan, Y., Han, S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010986 · Cited by 42
Turker, H. B., Riley, E., Luh, W., Colcombe, S. J., & Swallow, K. M. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118047 · Cited by 42
Falgàs, N., Allen, I. E., Spina, S., Grant, H. E., Piña‐Escudero, S. D., Merrilees, J. J., Gearhart, R., Rosen, H. J., Kramer, J. H., Seeley, W. W., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15203 · Cited by 42
Patterns of tau pathology identified with 18 F‐MK‐6240 PET imaging
Kreisl, W. C., Lao, P. J., Johnson, A. S., Tomljanovic, Z., Klein, J., Polly, K., Maas, B., Laing, K. K., Chesebro, A. G., Igwe, K. C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12384 · Cited by 42
Davey, D. A. (2013) · Women s Health · doi:10.2217/whe.13.22 · Cited by 42
The ‘a, b, c’s of pretangle tau and their relation to aging and the risk of Alzheimer’s Disease
Harley, C. W., Walling, S. G., Yuan, Q., & Martin, G. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.12.010 · Cited by 41
Noradrenergic neuromodulation in ageing and disease
Krohn, F., Lancini, E., Ludwig, M., Leiman, M., Guruprasath, G., Haag, L., Panczyszyn, J., Düzel, E., Hämmerer, D., & Betts, M. J. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105311 · Cited by 41
Durazzo, T. C., Mattsson, N., Weiner, M. W., & Initiative, A. D. N. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv075 · Cited by 41
HSV, Axonal Transport and Alzheimer‘s Disease:in Vitroandin VivoEvidence for Causal Relationships
Bearer, E. L. (2012) · Future Virology · doi:10.2217/fvl.12.81 · Cited by 41
Ma, Q., Jiang, L., Mao, J., Xu, W., & Huang, M. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8289 · Cited by 41
Association of antiretroviral therapy with brain aging changes among HIV-infected adults
Soontornniyomkij, V., Umlauf, A., Soontornniyomkij, B., Gouaux, B. D., Ellis, R. J., Levine, A. J., Moore, D. J., & Letendre, S. L. (2018) · AIDS · doi:10.1097/qad.0000000000001927 · Cited by 41
Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults
McSweeney, M., Binette, A. P., Meyer, P., Gonneaud, J., Bedetti, C., Ozlen, H., Labonté, A., Rosa‐Neto, P., Breitner, J. C. S., Poirier, J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008905 · Cited by 41
Schaler, A. W., Runyan, A. M., Clelland, C. L. T., Sydney, E. J., Fowler, S. L., Figueroa, H. Y., Shioda, S., Santa‐María, I., Duff, K., & Myeku, N. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba7394 · Cited by 41
Kelberman, M. A., Anderson, C. R., Chlan, E., Rorabaugh, J. M., McCann, K. E., & Weinshenker, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215546 · Cited by 42
Chronic Effects of Mild Neurotrauma: Putting the Cart Before the Horse?
Castellani, R. J., Perry, G., & Iverson, G. L. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000193 · Cited by 40
Braak, H., & Del Tredici, K. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz123 · Cited by 40
Self-citationSynapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 40
Caligiore, D., Giocondo, F., & Silvetti, M. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.09.007 · Cited by 40
van den Berg, M., Toen, D. V., Verhoye, M., & Keliris, G. A. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1081058 · Cited by 40
Hu, J., Sha, W., Yuan, S., Wu, J., & Huang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241915023 · Cited by 40
Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age
Pletniková, O., Rudow, G. L., Hyde, T. M., Kleinman, J. E., Ali, S. Z., Bharadwaj, R. A., Gangadeen, S., Crain, B. J., Fowler, D. R., Rubio, A. I., et al. (2015) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000071 · Cited by 40
Vandermeeren, M., Borgers, M., Kolen, K. V., Theunis, C., Vasconcelos, B., Bottelbergs, A., Wintmolders, C., Daneels, G., Willems, R., Dockx, K., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180404 · Cited by 40
Llibre‐Guerra, J. J., Li, Y., Schindler, S. E., Gordon, B. A., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., Hassenstab, J. J., Wang, G., Allegri, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17126 · Cited by 40
Novel Alzheimer’s disease subtypes identified using a data and knowledge driven strategy
Mitelpunkt, A., Galili, T., Kozlovski, T., Bregman, N., Shachar, N., Marcus-Kalish, M., & Benjamini, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-57785-2 · Cited by 40
Sun, W., Tang, Y., Qiao, Y., Ge, X., Mather, M., Ringman, J. M., & Shi, Y. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117301 · Cited by 40
Longitudinal validity of PET‐based staging of regional amyloid deposition
Jelistratova, I., Teipel, S. J., & Grothe, M. J. (2020) · Human Brain Mapping · doi:10.1002/hbm.25121 · Cited by 39
The neuropathology of intimate partner violence
Dams-O’Connor, K., Seifert, A. C., Crary, J. F., Delman, B. N., Bigio, M. R. D., Kovács, G. G., Lee, E. B., Nolan, A., Pruyser, A., Selmanovic, E., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02646-1 · Cited by 39
Bermejo‐Pareja, F., & del Ser, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020536 · Cited by 39
Modulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer’s Disease
Lee, E., & Chang, Y. (2025) · Cells · doi:10.3390/cells14030168 · Cited by 39
Arnsten, A. F. T., Tredici, K. D., Barthélemy, N. R., Gabitto, M. I., van Dyck, C. H., Lein, E. S., Braak, H., & Datta, D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70404 · Cited by 39
Self-citationAmyloid or tau: the chicken or the egg?
Mann, D. M. A., & Hardy, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1162-1 · Cited by 39
Metaxas, A., Thygesen, C., Kempf, S. J., Anzalone, M., Vaitheeswaran, R., Petersen, S., Landau, A. M., Audrain, H., Teeling, J. L., Darvesh, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52357-5 · Cited by 39
Metaxas, A., Thygesen, C., Briting, S. R. R., Landau, A. M., Darvesh, S., & Finsen, B. R. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00538 · Cited by 39
The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration
Engstrom, A., Walker, A. C., Moudgal, R. A., Myrick, D. A., Kyle, S. M., Bai, Y., Rowley, M. J., & Katz, D. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013552117 · Cited by 39
What’s in a Gene? The Outstanding Diversity of MAPT
Ruiz-Gabarre, D., Carnero-Espejo, A., Ávila, J., & García‐Escudero, V. (2022) · Cells · doi:10.3390/cells11050840 · Cited by 39
Memory markers in the continuum of the Alzheimer’s clinical syndrome
Parra, M. A., Calia, C., Pattan, V., & Sala, S. D. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01082-9 · Cited by 39
Non-cognitive symptoms and related conditions in the Alzheimer’s disease: a literature review
Raudino, F. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1424-7 · Cited by 39
Multiple Targets for the Management of Alzheimer’s Disease
Ahmad, S., Akhtar, S., Jamal, Q. M. S., Rizvi, S. M. D., Kamal, M. A., Khan, M. K., & Siddiqui, M. H. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161003165855 · Cited by 39
Shishido, H., Kishimoto, Y., Kawai, N., Toyota, Y., Ueno, M., Kubota, T., Kirino, Y., & Tamiya, T. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.06.066 · Cited by 38
Metadata
- Authors
- Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Braak, Heiko
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 70
- Issue
- 11
- Pages
- 960-969
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1993023011
- Cited by
- 2,194
- References
- 75
- Citations by year
- 2026: 152 · 2025: 192 · 2024: 260 · 2023: 233 · 2022: 192 · 2021: 235 · 2020: 182 · 2019: 144 · 2018: 121 · 2017: 110 · 2016: 100 · 2015: 85 · 2014: 78 · 2013: 65 · 2012: 42
- FWCI
- 41.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer Forschung Initiative (10810)
- Deutsche Forschungsgemeinschaft (TH624 4–1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, pathological staging, tauopathy, neurofibrillary tangles, amyloid plaques, locus coeruleus, brainstem, sporadic Alzheimer's disease, AT8 antibody
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Neurons, Cohort Studies, Amyloid beta-Peptides, Silver Staining, Neurofibrillary Tangles, tau Proteins, Disease Progression, Statistics, Nonparametric, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
